Related Experiment Video
Updated: Oct 6, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Reduced Incidence of Stroke in Patients with Gout Using Benzbromarone
Sheng-Wen Niu1,2,3,4, Chi-Chih Hung3,4, Hugo Y-H Lin2,3,4
1Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan.
Insights
Benzbromarone, a uricosuric agent, significantly reduces stroke incidence in gout patients. This study found fewer strokes in benzbromarone users compared to non-users, highlighting its potential protective effect against stroke in this population.
Area of Science:
- Rheumatology
- Cardiovascular Medicine
- Pharmacology
Background:
- Gout is a significant risk factor for atherosclerotic events, including stroke and myocardial infarction.
- Stroke prevalence is notably higher in individuals diagnosed with gout.
- Uricosuric agents are used to manage gout by lowering uric acid levels.
Purpose of the Study:
- To investigate the impact of benzbromarone, a uricosuric agent, on the incidence of stroke.
- To evaluate the efficacy of benzbromarone in mitigating stroke risk within the gout patient population.
Main Methods:
- Utilized data from the Taiwanese National Health Insurance Registration Database (NHIRD).
- Established a benzbromarone user cohort of 15,143 patients, matched with non-users from the gout population.
- Employed Cox proportional hazard regression analysis to assess stroke incidence.
Main Results:
- Benzbromarone users exhibited a significantly lower incidence of stroke compared to non-users.
- Hazard ratios for stroke were reduced in male benzbromarone users.
- Significant reductions in stroke incidence were observed in benzbromarone users aged 40-59 and ≥60 years.
Conclusions:
- Benzbromarone use is associated with a decreased incidence of stroke in patients with gout.
- The uricosuric agent benzbromarone demonstrates a protective effect against stroke in the gout population.
- Findings suggest benzbromarone may be a valuable therapeutic option for stroke prevention in gout patients.
Abstract:
Gout is strongly associated with the incidence of atherosclerotic events, including stroke and myocardial infarction. Considering the increased prevalence of stroke in the population with gout, the aim of this study was to evaluate the effects of benzbromarone, a uricosuric agent, on the incidence of stroke in the population with gout. We used data from the Taiwanese National Health Insurance Registration Database (NHIRD). The benzbromarone user cohort included 15,143 patients; each patient was age- and sex-matched with one non-user randomly selected from the population with gout. Cox proportional hazard regression analysis was conducted to estimate the effects of benzbromarone on the incidence of stroke in the population with gout. The incidence of stroke was significantly lower in benzbromarone users than in benzbromarone non-users. The HR for the incidence of stroke was lower in male benzbromarone users than in non-users. An analysis of three age groups (<40, 40-59, and ≥60 years) indicated that the HRs in those aged 40-59 years and ≥60 years were significantly lower among benzbromarone users than non-users. In the population with gout, the incidence of stroke was lower in benzbromarone users than in benzbromarone non-users.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Atherosclerosis III: Management
Antihypertensive Drugs: Thiazide-Class Diuretics
Peripheral Artery Disease III: Interprofessional Care
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Urinary Tract Calculi III: Medical Management

